GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially f...(is B Infection in the UK. The Hepatitis ...),Health

Date:5/18/2009

is B Infection in the UK. The Hepatitis B Foundation UK. http://www.hepb.org.uk/information/resources/rising_curve_chronic_hepatitis_b_infection_in_the_uk. (Last accessed 11.05.09)
6.   World Health Organisation Factsheet No 204 2008 revision. Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en/ (Last accessed 11.05.09)
7.   Mast EE et al. Transmission of blood borne pathogens during sports: risk and prevention. Ann Int Med 1995; 122 (4): 283
8.   De Franchis et al Consensus statement, EASL International Consensus Conference on Hepatitis B J Hepatol 2003; 39: S3-S25
9.   Zuckerman JN., Steffen R. J Travel Med (2000): 7; 170-174
10.   Ryder SD, Beckingham IJ ABC of diseases of liver, pancreas and biliary system: acute hepatitis 2001a BMJ; 322 (7280): 219-221
11.   Lin KW, Kircher JT. Hepatitis B. Am Fam Physician 2004; 69 (1): 75-82
12.   Zuckerman JN, Hoet B. Hepatitis B immunisation in travellers: poor risk perception and inadequate protection. Travel Med Inf Dis 2008; 6: 315-320

Enquiries:

Virgo HEALTH
Sarah Matthews   
sarah-jessica.matthews (at) virgohealth (dot) com
020 8939 2466 / 07968 366 526

Robert Kingston   
robert.kingston (at) virgohealth (dot) com   
020 8939 2479 / 07745 555 713

Tara Lanigan
tara.lanigan (at) virgohealth (dot) com   
020 8939 2463 / 07973 931 048

Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS <
'/>"/>

Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009
2. GlaxoSmithKline to Divest US Rights for Wellbutrin XL(R) to Biovail for $510 Million
3. GlaxoSmithKline Update: Influenza A (H1N1)
4. GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company
5. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
6. IADR and GlaxoSmithKline Consumer Healthcare announce winners of 2009 Innovation in Oral Care Awards
7. GlaxoSmithKline Consumer Healthcare to Reach 85 Percent of the Worlds Smokers with Quit Aids
8. GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia
9. Activplant Corporation Announces Global Agreement with GlaxoSmithKline
10. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
11. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL